Table 1.
Outcome of Other Viral CNS Infections in Control and THMOG Heterozygous Mice
| Virus | Dose (PFU) | C57Bl/6 controls
|
THMOG +/−
|
||||
|---|---|---|---|---|---|---|---|
| Clinical signs
|
Mortality | Clinical signs
|
Mortality (days)‡ | ||||
| Incidence | Score | Incidence* | Score (days)† | ||||
| Pichinde | 10E5 | 0/4 | N.A. | 0/4 | 0/4 | N.A. | 0/4 |
| TMEV | 10E5 | 0/5 | N.A. | 0/5 | 4/9 | 0.83 ± 0.59 (5) | 2/9 (5, 7) |
| CV B3 | 10E3 | 0/5 | N.A. | 0/5 | 2/5 | 0.70 ± 0.19 (15) | 1/5 (16) |
| 10E4 | 0/5 | N.A. | 0/5 | 7/7§ | 1.5 ± 0.14 (9) | 0/7 | |
The viruses were injected i.c. at the indicated doses in 2-week-old (CV B3) or 6-week-old (Pichinde and TMEV) mice. The table summarizes the follow-up of the clinical status and mortality in control (C57Bl/6) and autoimmune (heterozygous THMOG) animals. N.A., not applicable.
*
Number of mice with detectable clinical disease over total number in each group.
†
Highest average clinical score for each group, and the day after infection when it was observed.
‡
Number of deaths over total number of animals studied and timing of death.
§
P < 0.01, Fisher’s exact test.